Phone: +1 (240)-632-8810
Fax: +1 (240)-632-8820

About Us

Codex Biosolutions, Inc. is an advanced biotechnology company headquartered in the state of Maryland. We offer simple and high throughput solutions to aid scientists in solving complex problems. One of our primary focuses is on drug discovery. We are a leader in providing live cell based assays for novel compound screening. Our patented ACTOne based phosphodiesterase (PDE) and G-protein coupled receptor (GPCR) cell lines offer clients the ability to conduct efficient screenings of new compounds in a physiologically accurate, live cell based environment. We are the first in the world to produce commercially available cell lines to screen for compounds that target PDEs. We also provide a number of unique biochemical assay kits and specialty dyes. We strive to deliver high quality products that help our fellow scientists in the discovery process.

In the past five years, Codex participated Tox21, a federal Collaboration involving the NIH, EPA and FDA. We have developed assays for nuclear hormone receptors,  dye based mitochondria toxicity assays. Now we are developing the assays to evaluate the toxicities on TSHR and TRHR.

Latest News
August 15, 2013: Codex receives contract from NIH to develop assay to measure chemical toxicity
November 30, 2011: Codex receives award from US Army to develop drug that promotes soft tissue healing
September 23, 2011: Codex receives award from NIMH to develop assay for screening antipsychotic drugs

Activation of Hedgehog signaling by loss of GNAS causes heterotopic ossification 
Non Wash Calcium Dye Kit for Cardiomyocytes
Determination of Pro-arrhythmic Effects of Compounds in Human iPSC-Derived Cardiomyocytes Using RDSS/μCell Imaging Platform
Use of FDSS/μCell imaging platform for preclinical cardiac electrophysiology safety screening of compounds in human induced pluripotent stem cell-derived cardiomyocytes
PDE Cell Based Assay
A Cell-based PDE4 Assay in 1536-well Plate format for High Throughput Screening
A Novel Cell Based Assay for PDE Inhibitor Screenings
Development of a Novel PDE10A Cell Based Assay
Exploration and optimization of substituted triazolothiadiazines and triazolopyridazines as PDE4 inhibitors
Novel Cell-based Phosphodiesterase Assays
Stable Cell Line Service
Effect of the cytoplasmic domain on antigenic characteristics of HIV-1 envelope glycoprotein

Commensal bacteria make GPCR ligands that mimic human signalling molecules
Validation of a new ACTOne - FLIPR assay for measurement of peptide activity in plasma samples
Selective and Brain Penetrant Neuropeptide Y Y2 Receptor Antagonists Discovered by Whole-Cell High-Throughput Screening
Application of the BD ACTOneTM Technology for the High-Throughput Screening of Gs-Coupled Receptor Antagonists
Functional analysis of endogenous β-adrenergic receptor through fluorimetric monitoring of cyclic nucleotide-gated ion channel
Miniaturized Whole Cell-based GPCR cAMP Assay Using a Novel Detection System
Glutamate Is a Positive Autocrine Signal for Glucagon Release
New Applications of GPCR Analysis using BD ACTOne Technology
Act One: A Novel Real-time cAMP Assay using the FLIPR
Analysis of Gi-Coupled Receptors with BD ACTOne Technology
Miniaturized Cyclic Nucleotide-Gated (CNG) Channel Assays to Discover Neuropeptide Y Receptor Modulators
Quantitative High-Throughput Screening Using a Live-Cell cAMP Assay Identifies Small-Molecule Agonists of the TSH Receptor
Applications of multiplex cAMP and label-free assays using FDSS7000 and EPIC BT for studying potential biased signaling through the 5-HT7 receptor
M-MPI Dye Kit
Profiling of the Tox21 Chemical Collection for Mitochondrial Function to Identify Compounds that Acutely Decrease Mitochondrial Membrane Potential
Novel In Vitro Dye Based High-Throughput Toxicity Assay on Human Primary Cells
Application of a homogenous membrane potential assay to assess mitochondrial function